Although the majority of lesions reported in children and adolescents are benign, it should be recognized that oral malignant tumors do occur in children. The incidence of childhood malignancy is greatest in the 1st year of life, with the second peak to be found at 2–3 years of age. Many clinicians do believe that oral cancer is particularly aggressive in young patients, and is associated with poorer survival compared to adults. Numerous early reports of oral cancer in young adults concluded that the disease was more aggressive, and prognosis was poorer than in older adults. Purpose of this study is to make a literature review on the diagnostic methods of the tumors of oral cavity in children. Conclusion. Despite the progress in technology and medicine paraclinical examination methods in determining tumors of the oral cavity in children haven’t been developed and studied enough, thourder studies have to be done in order to create diagnostic protocols for the pediatric population.
Today, many people worldwide suffer from at least one vascular disease, one of these diseases is the hemangioma. A hemangioma is a vascular tumor which, in many cases, requires surgical intervention. Approximatively 30% of all hemangiomas are visible at birth. It occurs 5 time more often in females than in males, 83% occur on the head and neck area, the remaining 17 % appear throughout to the rest of the body, externally and internally. The biggest problem is the origin of this tumor. Could we understand how a hemangioma forms, we should be able to accelerate its disappearance, or prevent its growth in the first place.
The work was carried out within the State Program (1 year of activity-2020); „Modern personalized surgery in the diagnosis and complex treatment of tumors in children” N. 20.80009.8007.06. Analyzing the statistical data during the first year of activity of the project were registered 777 children with tumors, of which 279 (35.2%) primary and 498 (64.8%) – secondary. Of the 777 children, 455 (58.5%) had benign tumors and 97 (12.4%) had malignancies, 231 (29.7%) patients underwent surgical treatment, 455 (58.5%) chemotherapeutic treatment, 13 (1.9%) radiotherapy. Since March 2020, we have been active under the SARS-CoV-2 pandemic. We have developed a special proce- dure for the prevention of coronavirus infection. The COVID-19 pandemic is a new situation, unprecedented for the whole world, with many unknowns, including for the field of Pediatric Oncology and Dental Surgery. First of all, we highlight the adult or child oncological ill patient – as an emergency patient, therefore, the child with the malignant tumor must be treated urgently. Therefore, the treatment of oncological ill patients was conditionaly devided into 3 groups. Group I – primary patients with a diagnosis of malignant tumor, histologically confirmed, who must undergo treat- ment. Postponing this treatment is more dangerous than coronavirus. The treatment should be conducted under pandemic conditions: at distance, using disinfectants, masks, visiting relatives prohibition. Group II – pediatric patients, who at the beginning of the pandemic were at the treatment stage (chemo- or radiother- apy). If the concrete situation allows, the treatment continues. Hormone injection therapy can be performed at home by the specialized team (doctor and nurse). Group III – consisting of children – patients, who have undergone treatment and currently have no signs of disease, but require monitoring. These patients must be in quarantine. Oncological ill patients are considered to have compromised immunity. In adolescent and children, immunity is rela- tively good if there are no serious diseases such as systemic diseases. The tactics must be personalized, strictly individual. During 2020 we performed 3 types of surgical interventions in pediatric oncology: typical surgeries, enlarged surger- ies, combined surgeries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.